Physician profile
Christopher E Comeau
NPI 1184633273
$3,785.89
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $1,206 · 2021: $1,249 · 2022: $12.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,014.88 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.70 | 2019-2021 | |
| Novo Nordisk INC | $362.09 | 2019-2021 | |
| Glaxosmithkline, LLC. | $360.51 | 2019-2021 | |
| Lilly USA, LLC | $288.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $235.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $196.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $169.09 | 2019-2021 | |
| Allergan, INC. | $146.92 | 2019-2020 | |
| Amarin Pharma, INC. | $97.22 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $75.66 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $63.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.09 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $43.15 | 2019 | |
| Amgen INC. | $41.18 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31.12 | 2019-2021 | |
| Pfizer INC. | $27.53 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.14 | 2021 | |
| Eisai INC. | $13.80 | 2021 | |
| Optinose US, INC. | $11.48 | 2021 | |
| Abbvie INC. | $11.27 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Comeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.